The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Abstract
PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with advanced hepatocellular carcinoma (HCC). METHODS: ASCO convened an Expert Panel to conduct a systematic review of published phase III randomized controlled trials (2007-2020) on systemic therapy for advanced HCC and provide recommended care options for this patient population. RESULTS: Nine phase III randomized controlled trials met the inclusion criteria. RECOMMENDATIONS: Atezolizumab + bevacizumab (atezo + bev) may be offered as first-line treatment of most patients with advanced HCC, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1, and following management of esophageal varices, when present, according to institutional guidelines. Where there are contraindications to atezolizumab and/or bevacizumab, tyrosine kinase inhibitors sorafenib or lenvatinib may be offered as first-line treatment of patients with advanced HCC, Child-Pugh class A liver disease, and ECOG PS 0-1. Following first-line treatment with atezo + bev, and until better data are available, second-line therapy with a tyrosine kinase inhibitor may be recommended for appropriate candidates. Following first-line therapy with sorafenib or lenvatinib, second-line therapy options for appropriate candidates include cabozantinib, regorafenib for patients who previously tolerated sorafenib, or ramucirumab (for patients with α-fetoprotein ≥ 400 ng/mL), or atezo + bev where patients did not have access to this option as first-line therapy. Pembrolizumab or nivolumab are also reasonable options for appropriate patients following sorafenib or lenvatinib. Consideration of nivolumab + ipilimumab as an option for second-line therapy and third-line therapy is discussed. Further guidance on choosing between therapy options is included within the guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Cited by
BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
Self-citationImmunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Self-citationAdvances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
Self-citationMolecular pathogenesis and systemic therapies for hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Kelley, R. K., El-Khoueiry, A., Reeves, H. L., Wang, X. W., Gores, G. J., & Villanueva, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00357-2 · Cited by 498
Self-citationTherapeutic developments in pancreatic cancer
Hu, Z. I., & O’Reilly, E. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 413
Zhu, G.-Q., Tang, Z., Huang, R., Qu, W.-F., Fang, Y., Yang, R., Tao, C.-Y., Gao, J., Wu, X.-L., Sun, H.-X., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00529-z · Cited by 336
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beal, E., Finn, R. S., Gade, T. P., Goff, L., Gupta, S., Guy, J., Hoang, H. T., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02745 · Cited by 312
Self-citationβ-Catenin signaling in hepatocellular carcinoma
Xu, C., Xu, Z., Zhang, Y., Evert, M., Calvisi, D. F., & Chen, X. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154515 · Cited by 305
Lyu, N., Wang, X., Li, J.-B., Lai, J.-F., Chen, Q.-F., Li, S.-L., Deng, H.-J., He, M., Mu, L.-W., & Zhao, M. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01963 · Cited by 291
Qin, S., Kudo, M., Meyer, T., Bai, Y., Guo, Y., Meng, Z., Satoh, T., Marino, D., Assenat, E., Li, S., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.4003 · Cited by 265
Self-citationCappuyns, S., Corbett, V., Yarchoan, M., Finn, R. S., & Llovet, J. M. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2677 · Cited by 167
Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J., Popel, A. S., Anders, R. A., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01218-y · Cited by 140
“…was recently established as a preferred first-line standard of care for patients with unresectable HCC, and clinical efficacy has also been reported with multiple other anti-angiogenic/ immune checkpoint inhibitor (ICI) combinations (cabo-zantinib + atezolizumab and apatinib + camrelizumab) [4–10].”
BackgroundGPT-4 for Information Retrieval and Comparison of Medical Oncology Guidelines
Ferber, D., Wiest, I. C., Wölflein, G., Ebert, M. P., Beutel, G., Eckardt, J.-N., Truhn, D., Springfeld, C., Jäger, D., & Kather, J. N. (2024) · NEJM AI · doi:10.1056/aics2300235 · Cited by 92
Gajos-Michniewicz, A., & Czyz, M. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.050 · Cited by 89
Ding, Z., Dong, Z., Chen, Z., Hong, J., Yan, L., Li, H., Yao, S., Yan, Y., Yang, Y., Yang, C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733530 · Cited by 47
Yoon, J.-S., & Lee, C.-W. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00883-0 · Cited by 14
Metadata
- Authors
- Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beg, M. S., Brower, S. T., Gade, T. P., Goff, L., Gupta, S., Guy, J., Harris, W. P., Iyer, R., Jaiyesimi, I., Jhawer, M., Karippot, A., Kaseb, A. O., Kelley, R. K., Knox, J. J., Kortmansky, J., Leaf, A., Remak, W. M., Shroff, R. T., Sohal, D. P. S., Taddei, T. H., Venepalli, N. K., Wilson, A., Zhu, A. X., & Rose, M. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-12-20
- Volume
- 38
- Issue
- 36
- Pages
- 4317-4345
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3100629716
- Cited by
- 570
- References
- 63
- FWCI
- 44.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.